OncoCyte Corporation (AMEX:OCX) went down by -6.02% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $1.25 to trade ended Tuesday trading at $1.33. This is down from the $1.33 price recorded on Monday’s trading session. Thanks to this latest performance, OCX is closer to the higher price 52-week target of $7.00 and further from the lowest price target of $1.50. Its performance from the start of the year has also been negative, with OCX down by -44.44% year-to-date.
OncoCyte Corporation (OCX) started the day trading at $1.33 and recorded an intraday high of $1.38. It also recorded an intraday low of $1.25 during Tuesday’s trading session. OncoCyte Corporation is a very active stock that recorded a trading volume that is more than 41.31% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 1145081, which is more than 41.31 of the total average daily trading volume of 672.02K.
OncoCyte Corporation (AMEX:OCX) 2020 Performance Impressive
The increase in OCX’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of OCX currently stands at $3.51, which is higher than the current trading price of the stock by 64.39%. However, OCX’s current trading price is -2.46% lower than the 52-week low price of $1.22. In terms of trading volume, OncoCyte Corporation currently experienced healthy participation during the last trading session. 1145081 shares of OncoCyte Corporation were traded on the stock exchange on Tuesday, which is more than 41.31% of the 672.02K average trading volume of the stock.
The performance of the stock has been positive over the past year. OCX’s performance over the past one year has seen it plunge by -43.95%, while the stock has gone down by -49.60% in the last six months. The quarterly performance of OCX currently stands at -47.26%, and it is down by -52.29% in the last month. The only negative figure was from the weekly performance, which currently reads -61.30%. At the time of writing OCX’s report, the company has a total market cap of $91.05M, making it one of the largest publicly-traded companies in the world.OncoCyte Corporation also has over 33 employees all over the world.
OCX Insider Activities
For OncoCyte Corporation, insiders hold 41.00% of all company shares. The insider transactions over the past six months are up by 0.90%. During that period, insiders bought 1,097,216 shares in 4 transactions. In that same period, insiders sold 6,916 of their shares in 1 transactions. After these transactions, insiders at OncoCyte Corporation now hold 12.05M shares, which is over 34.54% of the total company stocks. Institutional investors currently hold a large chunk of the OCX shares, as they control 17.92% of the company’s total stock.
OCX Fundamental Analysis
For OncoCyte Corporation, the stock’s diluted earnings per share (EPS) stands at -0.48. In the coming year, analysts expect the EPS to be -0.37. The stock’s EPS growth this year is -5.00%, with analysts expecting almost a 1 growth in the earnings per share next week. In terms of revenue, OncoCyte Corporation’s quarterly sales (YOY) is shrinking at -0.10, which is higher than the average annual revenue of -17.40% over the past half a decade.
At the moment, OncoCyte Corporation’s Total Debt to Equity ratio stands at 0.09, and they have a long-term Debt to Equity ratio of 0.04.
OCX Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of OCX currently stands at -51.31%, while the SMA50 is -52.30%. The biggest one is the SMA200, which is currently reading -44.60% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 27.47.